Latest

The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ The Digital and Regulatory Frontier: Top 10 Technical and GMP Trends Shaping Pharma in 2026 ◆ Funding the Future: Inside the €75k Women TechEU and £10M Createch Grants for Startups and SMEs ◆ FDA Fires Warning Shot at Sanofi's Irish Plant Over Data Cover-Up and Altuviiio Quality Failings ◆ Top Universities in Ireland: Discover the Country's Leading Higher Education Institutions ◆ The Irish Startup Ecosystem: A Comprehensive Funding and Development Guide for Entrepreneurs ◆

Markets · 15 min delay

NBI4,187.6▲ +1.14%

PFE28.42▼ -0.38%

AZN74.18▲ +0.81%

NVO103.55▲ +2.07%

ROG261.40▼ -0.55%

ABBV174.92▲ +0.29%

EUR/USD1.0842▼ -0.12%

ISEQ9,241.3▲ +0.62%

NBI4,187.6▲ +1.14%

PFE28.42▼ -0.38%

AZN74.18▲ +0.81%

NVO103.55▲ +2.07%

ROG261.40▼ -0.55%

ABBV174.92▲ +0.29%

EUR/USD1.0842▼ -0.12%

Updated 04 Jul 2026 · HPRA open data

Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23 - Medicines in Ireland

3 authorised products containing Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23, from the HPRA register.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0–9

Showing 3 authorised medicines

Medicine	Active substance	Licence holder	Status
CRYSVITA 10 mg solution for injection EU/1/17/1262/001	Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23	Kyowa Kirin Holdings B.V.	—
CRYSVITA 20 mg solution for injection EU/1/17/1262/002	Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23	Kyowa Kirin Holdings B.V.	—
CRYSVITA 30 mg solution for injection EU/1/17/1262/003	Recombinant human igg1 monoclonal antibody to fibroblast growth factor 23	Kyowa Kirin Holdings B.V.	—

Cite this database

Priya Life Science (2026). Irish Medicines Database. Available at: https://priyalifescience.com/medicines (Accessed: 7 July 2026).

Data: Health Products Regulatory Authority (HPRA) open dataset (“Authorised or Transfer Pending Products”), licensed CC BY 4.0, refreshed daily. Regulatory information only — not medical advice.